AURX NUO THERAPEUTICS INC revenue, earnings and financials

For the quarter ended June 30, 2026, NUO THERAPEUTICS INC reported revenue of $1.77M (up 152.6% from a year earlier), net income of −$278K and diluted EPS of n/a; over the last four quarters revenue was $5.20M and net income −$2.01M; for the fiscal year ended December 2025 revenue was $3.31M, up 142.7% on the year before.

AURX annual revenue and earnings

• Fiscal year ended Dec 2025: revenue $3.31M, gross profit $2.22M, operating income −$2.52M, net income −$2.51M (margin -75.8%), EPS n/a
• Fiscal year ended Dec 2024: revenue $1.37M, gross profit $1.06M, operating income −$2.46M, net income −$2.32M (margin -170.2%), EPS n/a
• Fiscal year ended Dec 2023: revenue $609K, gross profit $482K, operating income −$3.17M, net income −$3.17M (margin -521.2%), EPS n/a
• Fiscal year ended Dec 2022: revenue $112K, gross profit $93.0K, operating income −$3.32M, net income −$3.17M (margin -2825.6%), EPS n/a
• Fiscal year ended Dec 2021: revenue $0, gross profit $0, operating income −$90.7K, net income −$90.7K (margin n/a), EPS −$0.03

AURX quarterly revenue and earnings

• Quarter ended Jun 30, 2026: revenue $1.77M (up 152.6% year over year), net income −$278K, EPS n/a
• Quarter ended Mar 31, 2026: revenue $1.30M (up 168.8% year over year), net income −$618K, EPS n/a
• Quarter ended Dec 31, 2025 (from the annual report): revenue $1.10M (up 177.8% year over year), net income −$578K, EPS n/a
• Quarter ended Sep 30, 2025: revenue $1.03M (up 178.2% year over year), net income −$538K, EPS n/a
• Quarter ended Jun 30, 2025: revenue $700K (up 92.0% year over year), net income −$650K, EPS n/a
• Quarter ended Mar 31, 2025: revenue $484K (up 106.5% year over year), net income −$746K, EPS n/a
• Quarter ended Dec 31, 2024 (from the annual report): revenue $395K (up 100.4% year over year), net income −$497K, EPS n/a
• Quarter ended Sep 30, 2024: revenue $371K (up 59.7% year over year), net income −$578K, EPS n/a
• Quarter ended Jun 30, 2024: revenue $365K (up 208.7% year over year), net income −$540K, EPS n/a
• Quarter ended Mar 31, 2024: revenue $235K (up 283.9% year over year), net income −$709K, EPS n/a
• Quarter ended Dec 31, 2023 (from the annual report): revenue $197K (up 166.2% year over year), net income −$653K, EPS n/a
• Quarter ended Sep 30, 2023: revenue $232K (up 507.2% year over year), net income −$791K, EPS n/a
• Quarter ended Jun 30, 2023: revenue $118K, net income −$872K, EPS n/a
• Quarter ended Mar 31, 2023: revenue $61.1K, net income −$856K, EPS n/a
• Quarter ended Dec 31, 2022 (from the annual report): revenue $74.0K, net income −$960K, EPS n/a
• Quarter ended Sep 30, 2022: revenue $38.3K, net income −$913K, EPS n/a
• Quarter ended Jun 30, 2022: revenue $0, net income −$924K, EPS n/a
• Quarter ended Mar 31, 2022: revenue $0, net income −$375K, EPS n/a
• Quarter ended Dec 31, 2021 (from the annual report): revenue $0, net income −$71.7K, EPS n/a
• Quarter ended Sep 30, 2021: revenue $0, net income −$6.75K, EPS n/a

AURX cash flow, buybacks and dividends

• Fiscal year ended Dec 2025: operating cash flow −$865K, share buybacks n/a
• Fiscal year ended Dec 2024: operating cash flow −$2.23M, share buybacks n/a
• Fiscal year ended Dec 2023: operating cash flow −$3.17M, share buybacks n/a
• Fiscal year ended Dec 2022: operating cash flow −$3.71M, share buybacks n/a
• Fiscal year ended Dec 2021: operating cash flow −$120K, share buybacks n/a

AURX balance sheet

• Jun 30, 2026: cash $449K, total assets $2.63M, total liabilities $4.16M, shareholders' equity −$1.54M
• Mar 31, 2026: cash $264K, total assets $1.95M, total liabilities $3.33M, shareholders' equity −$1.38M
• Dec 31, 2025: cash $549K, total assets $1.85M, total liabilities $2.80M, shareholders' equity −$957K
• Sep 30, 2025: cash $515K, total assets $1.93M, total liabilities $2.35M, shareholders' equity −$420K
• Jun 30, 2025: cash $316K, total assets $1.36M, total liabilities $2.18M, shareholders' equity −$825K
• Mar 31, 2025: cash $55.7K, total assets $1.15M, total liabilities $1.36M, shareholders' equity −$213K
• Dec 31, 2024: cash $284K, total assets $1.19M, total liabilities $676K, shareholders' equity $514K
• Sep 30, 2024: cash $684K, total assets $1.72M, total liabilities $829K, shareholders' equity $890K

What is AURX's revenue?

NUO THERAPEUTICS INC reported $5.20M of revenue over its last four quarters, through June 30, 2026.

Is AURX profitable?

No. NUO THERAPEUTICS INC lost $2.01M over the last four quarters.

AURX ownership and insider trades · All stocks